Cosmos Health posts record Q2 revenue $18.99M, up 29% YoY; adjusted gross profit +58%

Cosmos Health Inc.

2026-Q2 EPS reported -$0.17 revenue$36,914,268

Q2 2026 revenue $18.99M (+28.8% YoY); H1 revenue $36.91M (+29.7%); adjusted annualized run-rate exceeds $75M.
Q2 adjusted gross profit $1.84M, up 58.4%; adjusted gross margin expanded 165bps to 9.54%; op-ex grew ~half revenue rate.
Net loss widened to $6.09M in Q2 (vs $2.83M) on $2.65M non-cash fair-value charges; adjusted EBITDA improved to -$1.13M.
Total liabilities cut 13.3% to $40.79M; stockholders' equity up 12.2% to $20.67M; liabilities-to-assets ratio improved 550bps.
Repurchased 2.65M shares ($513K) in Q2; total 5.11M shares (~$1.11M) under new $5M buyback; LOI to acquire Doc Pharma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.